UVM Cancer Center

Dr. Steven Ades, M.D.

Claim this profile

University of Vermont Medical Center

Studies Cancer
Studies Rectal Cancer
10 reported clinical trials
26 drugs studied

Area of expertise

1Cancer
Steven Ades, M.D. has run 3 trials for Cancer. Some of their research focus areas include:
Stage IV
2Rectal Cancer
Steven Ades, M.D. has run 2 trials for Rectal Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.
University Of Vermont Medical Center
Image of trial facility.
Central Vermont Medical Center/National Life Cancer Treatment

Clinical Trials Steven Ades, M.D. is currently running

Image of trial facility.

Olanzapine vs Megestrol Acetate

for Cancer-Related Anorexia

This trial tests whether olanzapine or megestrol acetate is better at increasing appetite in patients with advanced cancer. These patients often struggle with eating and weight loss. Both medications aim to make them feel hungrier, helping them eat more and gain weight. Megestrol acetate is known for its effectiveness in increasing appetite in patients with cancer.
Recruiting2 awards Phase 31 criteria
Image of trial facility.

Blood Test and Immunotherapy

for Bladder Cancer

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.
Recruiting1 award Phase 2 & 310 criteria

More about Steven Ades, M.D.

Clinical Trial Related6 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Steven Ades, M.D. has experience with
  • Nivolumab
  • Irinotecan
  • Ipilimumab
  • FOLFOX Regimen
  • Radiation Therapy
  • Blood For CtDNA

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Steven Ades, M.D. specialize in?
Is Steven Ades, M.D. currently recruiting for clinical trials?
Are there any treatments that Steven Ades, M.D. has studied deeply?
What is the best way to schedule an appointment with Steven Ades, M.D.?
What is the office address of Steven Ades, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security